Equities Analysts Offer Predictions for A Q2 Earnings

Agilent Technologies, Inc. (NYSE:A) – Research analysts at Zacks Research reduced their Q2 2026 earnings per share estimates for Agilent Technologies in a report released on Monday, February 24th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $1.46 per share for the quarter, down from their previous forecast of $1.47. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.58%.

A number of other analysts have also recently weighed in on A. Bank of America lowered their price target on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Citigroup upped their target price on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Wells Fargo & Company cut their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a report on Monday, December 9th. Robert W. Baird decreased their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Sanford C. Bernstein cut their target price on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research note on Tuesday, November 26th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $146.15.

Agilent Technologies Trading Up 0.6 %

A stock opened at $127.83 on Thursday. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The firm has a market cap of $36.47 billion, a P/E ratio of 29.39, a P/E/G ratio of 3.64 and a beta of 1.07. Agilent Technologies has a 1-year low of $124.16 and a 1-year high of $155.35. The business’s 50 day moving average is $140.64 and its 200-day moving average is $139.14.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.78%. Agilent Technologies’s payout ratio is 22.76%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Flynn Zito Capital Management LLC increased its stake in Agilent Technologies by 3.8% in the fourth quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company’s stock valued at $251,000 after purchasing an additional 69 shares in the last quarter. IFP Advisors Inc increased its position in shares of Agilent Technologies by 17.7% in the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock valued at $62,000 after buying an additional 69 shares in the last quarter. Tiemann Investment Advisors LLC raised its stake in Agilent Technologies by 5.6% during the 4th quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company’s stock worth $191,000 after buying an additional 75 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in Agilent Technologies by 13.5% during the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after acquiring an additional 77 shares in the last quarter. Finally, Rothschild Investment LLC grew its stake in Agilent Technologies by 19.2% in the fourth quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock valued at $66,000 after acquiring an additional 79 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.